Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Alicante (21)

2024

  1. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645

2021

  1. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry

    PLoS ONE, Vol. 16, Núm. 6 June

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  3. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

  4. Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

    Frontiers in Oncology, Vol. 11

2020

  1. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

    Lung Cancer, Vol. 147, pp. 83-90

  2. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

2018

  1. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536

  2. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2017

  1. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

2016

  1. Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study

    Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711

2011

  1. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

    Clinical and Translational Oncology, Vol. 13, Núm. 6, pp. 411-418

2010

  1. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

1998

  1. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC)

    Lung Cancer, Vol. 22, Núm. 2, pp. 139-148

  2. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: Comparison of two phase II trials

    Clinical Cancer Research, Vol. 4, Núm. 11, pp. 2723-2728